Influence of endogenous DNA repair systems on PSMA-radioligand therapy in advanced prostate carcinoma

Dr. Particia Grabowski / Charité - Universitätsmedizin Berlin

ICPO support: € 149.358,68


Establishment of Teaching Modules for the ICPO Academy

Prof. Dr. Vikas Prasad / Universitätsklinikum Ulm

ICPO support: € 75.000,00


New SST2R-antagonists in the diagnosis of neuroendocrine tumors with PET/CT

Univ.-Prof. Dr. Frank Rösch / Johannes Gutenberg-Universität Mainz &
Dr. Theodosia Maina-Nock/National Center for Scientific Research Demokritos, Athens, Institute of Nuclear and Radiological Sciences, Energy, Technology and Safety

ICPO support: € 30.000,00

 

Novel drug delivery systems for improved therapy of Pca

Univ.-Prof. Dr. Frank Rösch / Johannes Gutenberg-Universität Mainz

ICPO support: € 30.000,00


Fellowship for the preparation of a comparative health economics study
“Radiomolecular Precision Oncology for Theranostics of recurrent/metastatic prostate cancer – a health-economic Comparison with conventional modus operandi.”

Prof. Dr. Richard P. Baum/Curanosticum Wiesbaden-Frankfurt

ICPO Support: € 70.000,00

 

Fellowship to carry out scientific projects and publish publications in the field of precision oncology
(Focus on SOPs and Best Practices)

Prof. Dr. Richard P. Baum/Curanosticum Wiesbaden-Frankfurt

ICPO Support: € 70.000,00


Performance of post-therapeutic dosimetries (TME radiopeptide therapy with FAP ligands)within the framework of a scientific cooperation with the company 3B Pharma (Berlin)

Prof. Dr. Richard P. Baum/Curanosticum Wiesbaden-Frankfurt/3B Pharma Berlin

ICPO Support: € 70.000,00


High-dose Botulinum Toxin combined with transdermal scopolamin to prevent salivary gland destruction by PSMA-radioligand therapy for metastatic prostate cancer

Prof. Dr. Richard Baum/Curanosticum Wiesbaden-Frankfurt/Prof. Jörg Müller, FA für Neurologie und Ärztlicher Direktor Vivantes Klinikum Spandau

ICPO Support: € 25.000,00